STAAR Surgical Company (STAA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 6, 2026, reports on events occurring on August 4, 2026. The filing details significant executive leadership changes at STAAR Surgical Company, a Delaware corporation headquartered in Lake Forest, California.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive appointments and associated compensation arrangements.
Material Changes
- Executive Appointment: Warren Foust was appointed President, Chief Executive Officer (CEO), and a new member of the Board of Directors, effective August 4, 2026. He previously served as Interim Co-CEO since February 2026 and COO since April 2023.
- Executive Transition: Deborah Andrews ceased serving as Interim Co-CEO. She continues as Chief Financial Officer and was appointed Executive Vice President (EVP) effective August 4, 2026.
- Compensation Structure: Mr. Foust's base salary is set at $730,000 annually. His compensation includes a target cash bonus of 70% of base salary for the period Jan 1–Jan 31, 2026, and 100% of base salary for the period Feb 1, 2026, onward.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary risks and contingencies relate to the vesting conditions of the new equity awards:
- Performance Hurdles: A significant portion of Mr. Foust's and Ms. Andrews' equity compensation is tied to stock price attainment hurdles of $50, $75, and $100 per share.
- Vesting Schedules: Equity awards include time-based vesting (over 3 to 4 years) and performance-based vesting contingent on stock price targets and continued employment.
- Severance and Change in Control: Mr. Foust is entitled to 18 months of base pay and benefits upon a "qualifying termination," with additional bonus entitlements in the event of a change in control.
Investor Verification Checklist
- Verify the specific grant dates for the "First Portion" and "Second Portion" of the 2027 equity awards, which depend on the opening of the insider trading window following Q2 2026 results.
- Review Exhibits 10.1 through 10.4 for the full legal terms of the offer letters and performance stock option notices.
- Confirm the current stock price relative to the $50, $75, and $100 performance hurdles to assess the probability of vesting for performance-based options.
- Monitor the company's Q2 2026 earnings release to determine the exact timing of the First Grant Date.